Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Ipsen Sa ADR (IPSEY)

Ipsen Sa ADR (IPSEY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare Business Wire - Wed May 20, 6:15AM CDT

Survey underscores the need for more resources, better preparation Ipsen's Healthcare-Shift.com offers a conversation guide, transition checklists and other...

IPN : 34.71 (-0.54%)
IPSEY : 44.8100 (-4.88%)
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC) Newswire.ca - Mon Nov 13, 2023

/CNW/ -- Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, rare disease and...

IPN : 34.71 (-0.54%)
IPSEY : 44.8100 (-4.88%)
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. Business Wire - Fri Jan 27, 2023

Regulatory News:

OTC.VN : 0.500 (-3.85%)
IPN : 34.71 (-0.54%)
IPSEY : 44.8100 (-4.88%)
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI Business Wire - Fri Jan 20, 2023

Regulatory News:

OTC.VN : 0.500 (-3.85%)
IPN : 34.71 (-0.54%)
IPSEY : 44.8100 (-4.88%)
Why These Two Biotech Stocks Blasted Higher This Week Motley Fool - Fri Jan 13, 2023

There's nothing like a big-premium buyout to send a company's share price to the moon.

CINC : 29.06 (-0.48%)
AZN : 169.64 (+0.22%)
ALBO : 44.15 (-0.23%)
IPSEY : 44.8100 (-4.88%)
SHAREHOLDER ALERT: Weiss Law Investigates Albireo Pharma, Inc. PR Newswire - Mon Jan 9, 2023

/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc....

ALBO : 44.15 (-0.23%)
IPSEY : 44.8100 (-4.88%)
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday Motley Fool - Mon Jan 9, 2023

The market is moving higher, and these small companies are helping.

COMP : 11.80 (+6.59%)
$NASX : 24,932.08 (-0.18%)
DCT : 18.99 (unch)
ALBO : 44.15 (-0.23%)
IPSEY : 44.8100 (-4.88%)
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases Business Wire - Mon Jan 9, 2023

Regulatory News:

OTC.VN : 0.500 (-3.85%)
ALBO : 44.15 (-0.23%)
IPN : 34.71 (-0.54%)
IPSEY : 44.8100 (-4.88%)
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva Business Wire - Fri Dec 23, 2022

Regulatory News:

OTC.VN : 0.500 (-3.85%)
IPN : 34.71 (-0.54%)
IPSEY : 44.8100 (-4.88%)
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy Business Wire - Thu Dec 8, 2022

Regulatory News:

OTC.VN : 0.500 (-3.85%)
IPN : 34.71 (-0.54%)
IPSEY : 44.8100 (-4.88%)

Barchart Exclusives

Altria Stock: Why Q2 Matters for Its High-Yield Appeal Barchart - Mon Jul 27, 6:30PM CDT
Altria's Dividend King reputation faces another important test in the upcoming Q2 earnings report as investors look beyond its shrinking cigarette business. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.